Please assess the completion status of the following clinical trial:

Trial Title: Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
key Inclusion Criteria:~* Morphologically confirmed diagnosis of MDS/CMMoL according to FAB or WHO classification, including RAEB-t and MDS/MPN~* International prognostic score-revised (IPSS-R) of \>3.5 (Intermediate, High or Very High)~* Previously untreated with hypomethylating agents for MDS/CMMoL~* Performance status of 0, 1 or 2 by the ECOG scale~* Adequate renal and liver function~* Female subjects of childbearing potential must have a negative serum pregnancy test at screening within 96 hours prior to the first study dose.~* Female subjects of childbearing potential and male subjects with partners of childbearing potential should ensure use of a highly effective method of birth control as defined by the investigator, for example, those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly during the study and for a period of 3 months following the last dose of any drug administered during the study.~Key Exclusion Criteria:~* Relapsed or refractory to hypomethylating agents~* Acute myeloid leukemia (AML), except those patients with RAEB-t who are not candidates for intensive AML therapy.~* Participated in any interventional study within 4 weeks of randomization or 5 half lives (whichever is longer).~* Received any hematopoietic growth factors within 14 days prior to screening.~* Prior malignancy or secondary malignancy within the prior 2 years (except in situ cervical cancer, squamous cell carcinoma or basal cell carcinoma of the skin).~* known diagnosis of human immunodeficiency virus or chronic active Hep B or C.~* Uncontrolled hypertension~* Impaired cardiac function, uncontrolled cardiac arrhythmias despite medications, or clinically significant cardiac disease~* Lack of recovery of prior adverse events to Grade ≤1 severity (National Cancer Institute Common Terminology Criteria for Adverse Events version 4) (except alopecia) due to therapy administered prior to the initiation of study drug dosing.~* Nursing or pregnant.~* Known allergy or hypersensitivity to any of the formulation components~* Any concurrent disease and/or medical condition that, in the opinion of the Investigator, would prevent the subject's participation.~* History of cranial nerve palsy.~* Being treated with anti-TNF therapies or has been treated with an anti-TNF therapy within 5 half-lives of randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- azacitidine with birinapant (Type: ACTIVE_COMPARATOR): Azacitidine 75 mg/m2 IV on days 1-5, 8 \& 9 OR days 1-7 and birinapant 13 mg/m2 IV twice a week (days 1 \& 4) for 3 out of 4 weeks
- Azacitidine and placebo (Type: PLACEBO_COMPARATOR): Azacitidine 75mg/m2 IV days 1-5, 8 \& 9 OR days 1-7 and placebo IV twice a week (days 1 \& 4) for 3 out of 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).